MCID: ANP009
MIFTS: 53

Anaplastic Oligodendroglioma

Categories: Cancer diseases, Neuronal diseases, Rare diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Anaplastic Oligodendroglioma

MalaCards integrated aliases for Anaplastic Oligodendroglioma:

Name: Anaplastic Oligodendroglioma 11 19 58 28 53 5 14 16 71 75

Characteristics:


Prevelance:

<1/1000000 (Europe) 1-9/1000000 (United States) 58

Age Of Onset:

Adult 58

Classifications:

Orphanet: 58  
Rare neurological diseases


External Ids:

Disease Ontology 11 DOID:7154
NCIt 49 C4326
ICD10 via Orphanet 32 C71.9
UMLS via Orphanet 72 C0334590
Orphanet 58 ORPHA251630
UMLS 71 C0334590

Summaries for Anaplastic Oligodendroglioma

GARD: 19 A rare glial tumor characterized by a grade III oligodendroglial tumour with focal or diffuse anaplastic features. It typically occurs in the supratentorial white matter. Histologically, the cells are enlarged and epithelioid with pleomorphic and increased size nuclei, a vesicular chromatin pattern and prominent nucleoli. Most patients present with seizures.

MalaCards based summary: Anaplastic Oligodendroglioma is related to anaplastic oligodendroglioma, idh-mutant and 1p/19q-codeleted and oligoastrocytoma, and has symptoms including headache and seizures. An important gene associated with Anaplastic Oligodendroglioma is IDH2 (Isocitrate Dehydrogenase (NADP(+)) 2), and among its related pathways/superpathways are ERK Signaling and Signal Transduction. The drugs Dabrafenib and Procarbazine have been mentioned in the context of this disorder. Affiliated tissues include brain, eye and breast, and related phenotypes are Decreased viability and Decreased viability in pancreas lineage

Orphanet: 58 A rare glial tumor characterized by a grade III oligodendroglial tumour with focal or diffuse anaplastic features. It typically occurs in the supratentorial white matter. Histologically, the cells are enlarged and epithelioid with pleomorphic and increased size nuclei, a vesicular chromatin pattern and prominent nucleoli. Most patients present with seizures.

Disease Ontology: 11 An oligodendroglioma that is characterized by focal or diffuse malignant morphologic features (prominent nuclear pleomorphism, mitoses, and increased cellularity).

Wikipedia: 75 Anaplastic oligodendroglioma is a neuroepithelial tumor which is believed to originate from... more...

Related Diseases for Anaplastic Oligodendroglioma

Diseases related to Anaplastic Oligodendroglioma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 295)
# Related Disease Score Top Affiliating Genes
1 anaplastic oligodendroglioma, idh-mutant and 1p/19q-codeleted 33.0 IDH2 IDH1
2 oligoastrocytoma 31.5 MGMT IDH2 GFAP
3 oligodendroglioma 30.7 PTEN POT1 PDGFRA OLIG2 OLIG1 MGMT
4 gangliocytoma 30.7 PTEN IDH1 GFAP
5 cellular ependymoma 30.5 MGMT GFAP EGFR
6 high grade glioma 30.5 PTEN PDGFRA MGMT MDM2 KDR GFAP
7 central neurocytoma 30.4 OLIG2 IDH1 GFAP
8 clear cell ependymoma 30.4 OLIG2 GFAP
9 cerebral lymphoma 30.4 MGMT IDH1
10 brain cancer 30.4 PTEN PDGFRA OLIG2 OLIG1 MGMT MDM2
11 spinal cord oligodendroglioma 30.2 MGMT LGALS3 IDH1 GFAP EGFR
12 brain glioma 30.2 PTEN PDGFRA OLIG2 MGMT IDH2 IDH1
13 retinoblastoma 30.2 MDM2 CDKN2C CDKN2B CDKN2A CDK4
14 glioma 30.2 PTEN MGMT MDM2 IDH2 IDH1 EGFR
15 lynch syndrome 30.1 PTEN MGMT IDH1 EGFR CDKN2A CDK4
16 leukemia, acute lymphoblastic 30.1 IGFBP2 CDKN2C CDKN2B CDKN2A CDK4
17 adenocarcinoma 30.1 PTEN MDM2 KDR EGFR CDKN2A CDK4
18 meningioma, familial 30.1 PTEN OLIG2 MGMT MDM2 IDH1 GFAP
19 lymphoma 30.0 MGMT MDM2 EGFR CDKN2C CDKN2B CDKN2A
20 mixed glioma 29.9 PTEN PDGFRA OLIG2 MGMT IDH2 IDH1
21 low grade glioma 29.9 PTEN PDGFRA OLIG2 MGMT IDH2 IDH1
22 glioblastoma 29.9 PTEN PDGFRA OLIG2 MGMT MDM2 KDR
23 myelodysplastic syndrome 29.8 PDGFRA KDR IDH2 IDH1 CDKN2C CDKN2B
24 pilocytic astrocytoma 29.6 PTEN PDGFRA OLIG2 MGMT LGALS3 IDH2
25 anaplastic astrocytoma 29.5 PTEN PDGFRA OLIG2 OLIG1 MGMT MDM2
26 prostate cancer 29.4 STMN1 PTEN MGMT MDM2 LGALS3 KDR
27 medulloblastoma 29.4 STMN1 PTEN PDGFRA OLIG2 MGMT MDM2
28 glioma susceptibility 1 11.0
29 tonsillar pillar cancer 10.5 EGFR CDKN2A
30 diffuse glioma, h3 g34 mutant 10.4 MGMT CDKN2A
31 vulvar seborrheic keratosis 10.4 PTEN CDKN2A
32 third ventricle chordoid glioma 10.4 OLIG2 GFAP
33 factor vii deficiency 10.4
34 anaplastic oligoastrocytoma 10.4
35 hereditary melanoma 10.4 CDKN2A CDK4
36 glottis squamous cell carcinoma 10.4 PTEN EGFR
37 enchondroma 10.4 IDH2 IDH1
38 kidney liposarcoma 10.4 MDM2 CDK4
39 papillary squamous carcinoma 10.4 EGFR CDKN2A
40 deep leiomyoma 10.4 PDGFRA GFAP
41 intracranial chondrosarcoma 10.4 IDH2 IDH1
42 protoplasmic astrocytoma 10.4 MGMT IDH2
43 childhood liposarcoma 10.4 MDM2 CDK4
44 vaginal cancer 10.4 PTEN EGFR CDKN2A
45 esophagus verrucous carcinoma 10.4 MDM2 EGFR CDKN2A
46 idh-mutant anaplastic astrocytoma 10.4 MGMT IDH2 IDH1
47 idh-wildtype anaplastic astrocytoma 10.4 MGMT IDH2 IDH1
48 vulvar disease 10.4 PTEN EGFR CDKN2A
49 adult brain stem glioma 10.4 MGMT IDH1
50 adult oligodendroglioma 10.4 OLIG2 IDH2 IDH1

Graphical network of the top 20 diseases related to Anaplastic Oligodendroglioma:



Diseases related to Anaplastic Oligodendroglioma

Symptoms & Phenotypes for Anaplastic Oligodendroglioma

UMLS symptoms related to Anaplastic Oligodendroglioma:


headache; seizures

GenomeRNAi Phenotypes related to Anaplastic Oligodendroglioma according to GeneCards Suite gene sharing:

25 (show all 13)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-1 10.51 EGFR
2 Decreased viability GR00055-A-2 10.51 EGFR
3 Decreased viability GR00173-A 10.51 PDGFRA
4 Decreased viability GR00221-A-1 10.51 CDKN2A EGFR KDR PDGFRA POT1 CDKN2C
5 Decreased viability GR00221-A-2 10.51 KDR
6 Decreased viability GR00221-A-3 10.51 CDKN2A KDR PDGFRA POT1
7 Decreased viability GR00221-A-4 10.51 CDKN2A EGFR KDR PDGFRA POT1
8 Decreased viability GR00249-S 10.51 KDR PDGFRA CDKN2C
9 Decreased viability GR00301-A 10.51 CDKN2C
10 Decreased viability GR00402-S-2 10.51 PDGFRA
11 no effect GR00402-S-1 10.19 CDK4 CDKN2A CDKN2B CDKN2C CIC EGFR
12 no effect GR00402-S-2 10.19 CDK4 CDKN2A CDKN2B CDKN2C CIC EGFR
13 Decreased viability in pancreas lineage GR00235-A 8.65 IDH1

MGI Mouse Phenotypes related to Anaplastic Oligodendroglioma:

45 (show all 21)
# Description MGI Source Accession Score Top Affiliating Genes
1 nervous system MP:0003631 10.47 CDK4 CDKN2A CDKN2C CIC EGFR GFAP
2 homeostasis/metabolism MP:0005376 10.4 CDK4 CDKN2A CDKN2B CDKN2C EGFR GFAP
3 growth/size/body region MP:0005378 10.39 CDK4 CDKN2A CDKN2C CIC EGFR GFAP
4 neoplasm MP:0002006 10.37 CDK4 CDKN2A CDKN2B CDKN2C EGFR IDH2
5 cellular MP:0005384 10.33 CDK4 CDKN2A CDKN2B CDKN2C EGFR GFAP
6 normal MP:0002873 10.28 CDK4 EGFR GFAP IGFBP2 KDR MDM2
7 immune system MP:0005387 10.28 CDK4 CDKN2A CDKN2B CDKN2C EGFR GFAP
8 muscle MP:0005369 10.25 CDK4 CDKN2A EGFR GFAP KDR MDM2
9 cardiovascular system MP:0005385 10.25 CDK4 CDKN2A CDKN2C EGFR GFAP IDH2
10 endocrine/exocrine gland MP:0005379 10.24 CDK4 CDKN2A CDKN2B CDKN2C EGFR LGALS3
11 no phenotypic analysis MP:0003012 10.23 CDKN2A CDKN2B EGFR KDR MDM2 MGMT
12 renal/urinary system MP:0005367 10.21 CDK4 CDKN2B CDKN2C EGFR IGFBP2 LGALS3
13 pigmentation MP:0001186 10.14 CDK4 CDKN2A EGFR MDM2 PDGFRA POT1
14 liver/biliary system MP:0005370 10.14 CDK4 CDKN2A EGFR IGFBP2 KDR LGALS3
15 digestive/alimentary MP:0005381 10.13 CDK4 CDKN2A EGFR GFAP LGALS3 MDM2
16 respiratory system MP:0005388 10.11 CDKN2A CDKN2C CIC EGFR IDH1 KDR
17 reproductive system MP:0005389 10.02 CDK4 CDKN2A CDKN2B CDKN2C EGFR LGALS3
18 skeleton MP:0005390 10 CDK4 CDKN2A EGFR IDH1 IDH2 KDR
19 hematopoietic system MP:0005397 10 CDK4 CDKN2A CDKN2B CDKN2C EGFR IDH1
20 mortality/aging MP:0010768 9.89 CDK4 CDKN2A CDKN2B CDKN2C CIC EGFR
21 integument MP:0010771 9.4 CDK4 CDKN2A CDKN2B CDKN2C EGFR KDR

Drugs & Therapeutics for Anaplastic Oligodendroglioma

Drugs for Anaplastic Oligodendroglioma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 156)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Dabrafenib Approved, Investigational Phase 4 1195765-45-7 44462760
2
Procarbazine Approved, Investigational Phase 3 671-16-9 4915
3
Topotecan Approved, Investigational Phase 2 123948-87-8, 119413-54-6 60699 60700
4
Melphalan Approved Phase 1, Phase 2 148-82-3 4053 460612
5
Etoposide Approved Phase 1, Phase 2 33419-42-0 36462
6
Picropodophyllin Approved, Investigational Phase 1, Phase 2 518-28-5, 477-47-4 10607 72435
7
Mechlorethamine Approved, Investigational Phase 1, Phase 2 51-75-2 4033
8
Sorbitol Approved, Investigational Phase 1, Phase 2 69-65-8, 50-70-4 453 6251 5780
9
Aflibercept Approved Phase 2 862111-32-8 124490314
10
Carmustine Approved, Investigational Phase 2 154-93-8 2578
11
Romidepsin Approved, Investigational Phase 1, Phase 2 128517-07-7 5352062
12
Gefitinib Approved, Investigational Phase 1, Phase 2 184475-35-2 123631
13
Mercaptopurine Approved Phase 2 50-44-2 667490
14
Streptozocin Approved, Investigational Phase 2 18883-66-4, 66395-18-4 29327
15
Nintedanib Approved Phase 2 656247-17-5 135423438 9809715
16
Vincristine Approved, Investigational Phase 2 2068-78-2, 57-22-7 5978
17
Carboplatin Approved Phase 2 41575-94-4 10339178 38904
18
Busulfan Approved, Investigational Phase 2 55-98-1 2478
19
Thiotepa Approved, Investigational Phase 2 52-24-4 5453
20
Temozolomide Approved, Investigational Phase 2 85622-93-1 5394
21
Bevacizumab Approved, Investigational Phase 1, Phase 2 216974-75-3 135329020
22
Lopinavir Approved Phase 2 192725-17-0 92727
23
Ritonavir Approved, Investigational Phase 2 155213-67-5 392622
24
D-Phenylalanine Approved, Experimental, Investigational, Nutraceutical Phase 1, Phase 2 63-91-2, 673-06-3 6140 71567
25
D-Tyrosine Approved, Experimental, Investigational, Nutraceutical Phase 2 133585-56-5, 60-18-4, 556-02-5 1153 6057
26
Etoposide phosphate Phase 1, Phase 2 16760419
27 Keratolytic Agents Phase 1, Phase 2
28 Nitrogen Mustard Compounds Phase 1, Phase 2
29
Sodium thiosulfate Phase 1, Phase 2
30 Antitubercular Agents Phase 1, Phase 2
31 diuretics Phase 1, Phase 2
32 Endothelial Growth Factors Phase 2
33 Mitogens Phase 2
34 Bendamustine Hydrochloride Phase 2
35
Imatinib Mesylate Phase 1, Phase 2 220127-57-1
36 Immunoglobulin G Phase 1, Phase 2
37 Antimitotic Agents Phase 2
38 Tubulin Modulators Phase 2
39 Immunosuppressive Agents Phase 2
40 Alkylating Agents Phase 2
41 Antineoplastic Agents, Alkylating Phase 2
42 Anticonvulsants Phase 2
43 Anti-Infective Agents Phase 2
44 Immunologic Factors Phase 1, Phase 2
45 Angiogenesis Inhibitors Phase 1, Phase 2
46 Immunoglobulins, Intravenous Phase 1, Phase 2
47 Immunoglobulins Phase 1, Phase 2
48 Antibodies, Monoclonal Phase 1, Phase 2
49 Antibodies Phase 1, Phase 2
50 Antineoplastic Agents, Immunological Phase 1, Phase 2

Interventional clinical trials:

(show top 50) (show all 99)
# Name Status NCT ID Phase Drugs
1 An Open Label, Multi-center Roll-over Study to Assess Long-term Effect in Pediatric Patients Treated With Tafinlar (Dabrafenib) and/or Mekinist (Trametinib) Recruiting NCT03975829 Phase 4 dabrafenib;trametinib
2 Phase 3 Study of Carmustine Sustained Release Implant (CASANT) to Treat Newly Diagnosed Malignant Glioma Unknown status NCT01656980 Phase 3 Carmustine
3 PHASE III STUDY OF ADJUVANT PROCARBAZINE, CCNU AND VINCRISTINE CHEMOTHERAPY IN PATIENTS WITH HIGHLY ANAPLASTIC OLIGODENDROGLIOMA Completed NCT00002840 Phase 3 lomustine;procarbazine hydrochloride;vincristine sulfate
4 Phase I/II Clinical Trial of the Safety, Tolerability, and Anti-tumor Efficacy of the IGF-1R Inhibitor, AXL1717 (Picropodophyllin), in the Treatment of Recurrent Malignant Astrocytomas Unknown status NCT01721577 Phase 1, Phase 2 AXL1717
5 Phase II Trial of Continuous Dose Temozolomide in Patients With Newly Diagnosed Pure and Mixed Anaplastic Oligodendroglioma Completed NCT00400816 Phase 2 temozolomide
6 The Efficacy and Safety of Temozolomide in Patients With Relapsed or Advanced Anaplastic Oligodendroglioma and Oligoastrocytoma: a Multicenter, Single-arm, Phase II Trial Completed NCT01847235 Phase 2 Temozolomide
7 A Phase II Study of Topotecan in Patients With Anaplastic Oligodendroglioma or Anaplastic Mixed Oligoastrocytoma Completed NCT00003372 Phase 2 topotecan hydrochloride
8 Phase II Trial of Continuous Dose Temozolomide in Patients With Newly Diagnosed Anaplastic Oligodendroglioma and Mixed Oligoastrocytoma Completed NCT00362570 Phase 2 Temozolomide
9 Phase I/II Study of Carboplatin, Melphalan and Etoposide Phosphate in Conjunction With Osmotic Opening of the Blood-Brain Barrier and Delayed Intravenous Sodium Thiosulfate Chemoprotection, in Previously Treated Subjects With Anaplastic Oligodendroglioma or Oligoastrocytoma Completed NCT00303849 Phase 1, Phase 2 Carboplatin;Etoposide;Etoposide Phosphate;Mannitol;Melphalan;Sodium Thiosulfate
10 Phase II Treatment of Adults With Newly Diagnosed, Progressive or Recurrent Primary Malignant Anaplastic Oligodendroglioma With Temodal Completed NCT00003465 Phase 2 temozolomide
11 A Phase II Trial of Intensive Chemotherapy and Autotransplantation for Patients With Newly Diagnosed Anaplastic Oligodendroglioma Completed NCT00003101 Phase 2 busulfan;lomustine;procarbazine hydrochloride;thiotepa;vincristine sulfate
12 Cilengitide (EMD 121974) (IND# 59073) in Recurrent or Progressive and Refractory Childhood High-Grade Glioma Completed NCT00679354 Phase 2 cilengitide
13 A Phase II Study of Bendamustine in the Treatment of Recurrent High-Grade Gliomas (Anaplastic Gliomas and Glioblastoma) Completed NCT00823797 Phase 2 Bendamustine Hydrochloride
14 A Randomized Phase II Trial of Bevacizumab to Control Brain Radiation Damage Completed NCT00492089 Phase 2 bevacizumab;placebo
15 A Phase 2 Trial of Tandutinib in Combination With Bevacizumab for Patients With Recurrent High-Grade Gliomas Completed NCT00667394 Phase 2 MLN-518 (Tandutinib)
16 Phase II Single Arm Trial of VEGF Trap in Patients With Recurrent Temozolomide-Resistant Malignant Gliomas Completed NCT00369590 Phase 2
17 A Phase I-II Trial of Depsipeptide in Patients With Recurrent High-Grade Gliomas Completed NCT00085540 Phase 1, Phase 2 depsipeptide
18 A Randomized Phase II Trial of Vandetanib (ZD6474) in Combination With Carboplatin Versus Carboplatin Alone Followed by Vandetanib Alone in Adults With Recurrent High-Grade Gliomas Completed NCT00995007 Phase 2 ZD6474 (Vandetanib);Carboplatin
19 Phase I/II Study of OSI-774 (Erlotinib) and CCI-779 (Temsirolimus) in Patients With Recurrent Malignant Glioma Completed NCT00112736 Phase 1, Phase 2 erlotinib;temsirolimus
20 Phase I/II Trial of Gefitinib and Radiation in Pediatric Patients Newly Diagnosed With Brain Stem Tumors or Incompletely Resected Supratentorial Malignant Gliomas With Phase II Limited to Brain Stem Tumors Completed NCT00042991 Phase 1, Phase 2 gefitinib
21 Phase I/II Trial of Imatinib Mesylate; (Gleevec; STI571) in Treatment of Recurrent Oligodendroglioma and Mixed Oligoastrocytoma Completed NCT00049127 Phase 1, Phase 2 Imatinib Mesylate
22 Phase I/II Trial of Temsirolimus and Perifosine for Recurrent or Progressive Malignant Gliomas Completed NCT01051557 Phase 1, Phase 2 Perifosine;Temsirolimus
23 A Phase I/II Trial of OSI-774 in Patients With Recurrent Malignant Gliomas and Malignant Gliomas Post Radiation Therapy Completed NCT00045110 Phase 1, Phase 2 erlotinib hydrochloride
24 Phase I/Comparative Randomized Phase II Trial of TRC105 Plus Bevacizumab Versus Bevacizumab in Bevacizumab-Naive Patients With Recurrent Glioblastoma Multiforme Completed NCT01648348 Phase 1, Phase 2
25 Phase II Study of Carmustine, Streptozocin, and Mercaptopurine for Refractory or Recurrent Brain Neoplasms Completed NCT00004688 Phase 2 carmustine;mercaptopurine;streptozocin
26 Phase II Trial of Triple Receptor Tyrosine Kinase Receptor Inhibitor BIBF 1120 in Recurrent High-Grade Gliomas Completed NCT01380782 Phase 2 BIBF 1120
27 Phase II Trial of Treatment Intensification for IDH Wildtype, Non-Histological Glioblastoma, Gliomas (IDH Wildtype Lower Grade Glioma Treatment Intensification) Recruiting NCT04623931 Phase 2 Temozolomide
28 A Phase II Trial of Intensive Chemotherapy and Autotransplantation for Patients With Newly Diagnosed Anaplastic Oligodendroglioma Active, not recruiting NCT00588523 Phase 2 temozolomide followed by high dose busulfan and thiotepa
29 Phase II Open-label Global Study to Evaluate the Effect of Dabrafenib in Combination With Trametinib in Children and Adolescent Patients With BRAF V600 Mutation Positive Low Grade Glioma (LGG) or Relapsed or Refractory High Grade Glioma (HGG) Active, not recruiting NCT02684058 Phase 2 dabrafenib;trametinib;Carboplatin with vincristine
30 Phase II Trial of Ritonavir/Lopinavir in Patients With Progressive of Recurrent High-Grade Gliomas Terminated NCT01095094 Phase 2 ritonavir;lopinavir
31 A Phase II Trial of Talampanel in Patients With Recurrent High-Grade Gliomas. Terminated NCT00062504 Phase 2 Talampanel
32 Phase I/II Study of R04929097 With Bevacizumab in Patients With Recurrent Malignant Glioma Terminated NCT01189240 Phase 1, Phase 2 gamma-secretase/Notch signalling pathway inhibitor RO4929097
33 A Phase II Study of the Efficacy of Hypofractionated Radiation Therapy With Bevacizumab and Temozolomide Followed by Maintenance Temozolomide and Bevacizumab for Recurrent High-Grade Gliomas Terminated NCT01478321 Phase 2 Temozolomide
34 A Phase I Dose-finding and Pharmacokinetic Study of Intravenous RTA 744 Injection in Patients With Recurrent or Refractory Anaplastic Astrocytoma (AA), Anaplastic Oligodendroglioma (AO), Anaplastic Mixed Oligo-astrocytoma (AOA), Glioblastoma Multiforme (GBM) or Gliosarcoma (GS), With or Without Concurrent Treatment With Enzyme-inducing Anticonvulsant Therapy Completed NCT00526812 Phase 1 RTA 744;RTA 744 injection
35 Phase I Study of Mebendazole Therapy for Recurrent/Progressive Pediatric Brain Tumors Completed NCT02644291 Phase 1 Mebendazole
36 Phase I Trial of Aflibercept (VEGF Trap) With Radiation Therapy and Concomitant and Adjuvant Temozolomide in Patients With Malignant Glioma Completed NCT00650923 Phase 1 ziv-aflibercept;temozolomide
37 A Phase I Trial of p28 (NSC745104), a Non-HDM2 Mediated Peptide Inhibitor of p53 Ubiquitination in Pediatric Patients With Recurrent or Progressive CNS Tumors Completed NCT01975116 Phase 1 azurin-derived cell-penetrating peptide p28
38 A Phase I Trial of Nanoliposomal CPT-11 (NL CPT-11) in Patients With Recurrent High-Grade Gliomas Completed NCT00734682 Phase 1 Nanoliposomal CPT-11
39 Neural Stem Cell Oncolytic Adenoviral Virotherapy of Newly Diagnosed Malignant Glioma Completed NCT03072134 Phase 1
40 Phase I Trial of a Measles Virus Derivative Producing CEA (MV-CEA) in Patients With Recurrent Glioblastoma Multiforme (GBM) Completed NCT00390299 Phase 1
41 A Phase 1 Ascending Dose Trial of the Safety and Tolerability of Toca 511, a Retroviral Replicating Vector, Administered Intravenously Prior to, and Intracranially at the Time of, Subsequent Resection for Recurrent HGG & Followed by Treatment With Extended-Release 5-FC Completed NCT01985256 Phase 1 Toca FC
42 A Phase I Study of Cytosine Deaminase-Expressing Neural Stem Cells in Combination With Oral 5-Fluorocytosine and Leucovorin for the Treatment of Recurrent High-Grade Gliomas Completed NCT02015819 Phase 1 flucytosine;leucovorin calcium
43 A Phase I Trial of BAY 43-9006 for Patients With Recurrent or Progressive Malignant Glioma Completed NCT00093613 Phase 1 sorafenib tosylate
44 Phase I Dose Finding Study of Sorafenib in Combination With Radiation Therapy and Temozolomide as a First Line Treatment of Patients With High Grade Glioma Completed NCT00884416 Phase 1 Sorafenib dose escalation
45 A Phase I Clinical Trial Evaluating Cellular Immunotherapy With Intratumoral Alloreactive Cytotoxic T Lymphocytes and Interleukin-2 for the Treatment of Recurrent Malignant Gliomas or Meningiomas Completed NCT01144247 Phase 1 alloreactive CTL
46 Phase I Study of OSI-774 (NSC 718781) for Solid Tumors in Patients With Hepatic or Renal Dysfunction Completed NCT00030498 Phase 1 erlotinib hydrochloride
47 A Phase 1, Pharmacokinetic and Pharmacodynamic Study of the Combination of RO4929097 and Cediranib in Patients With Advanced Solid Tumors Completed NCT01131234 Phase 1 Gamma-Secretase Inhibitor RO4929097;Cediranib Maleate
48 Intracerebral Convection Enhanced Delivery of Carboplatin for Treatment of Recurrent High-grade Gliomas Completed NCT01644955 Phase 1 carboplatin
49 Phase I Study of Cellular Immunotherapy for Recurrent/Refractory Malignant Glioma Using Intratumoral Infusions of GRm13Z40-2, An Allogeneic CD8+ Cytolitic T-Cell Line Genetically Modified to Express the IL 13-Zetakine and HyTK and to be Resistant to Glucocorticoids, in Combination With Interleukin-2 Completed NCT01082926 Phase 1
50 Pilot Imaging Study to Assess the Distribution of IL13-PE38QQR Cytotoxin Infusions in Patients With Recurrent, Resectable, Supratentorial Malignant Glioma Completed NCT00064779 Phase 1 IL13-PE38QQR

Search NIH Clinical Center for Anaplastic Oligodendroglioma

Genetic Tests for Anaplastic Oligodendroglioma

Genetic tests related to Anaplastic Oligodendroglioma:

# Genetic test Affiliating Genes
1 Anaplastic Oligodendroglioma 28

Anatomical Context for Anaplastic Oligodendroglioma

Organs/tissues related to Anaplastic Oligodendroglioma:

MalaCards : Brain, Eye, Breast, Endothelial, Spinal Cord, Bone Marrow, Liver

Publications for Anaplastic Oligodendroglioma

Articles related to Anaplastic Oligodendroglioma:

(show top 50) (show all 629)
# Title Authors PMID Year
1
IGFBP2 is a candidate biomarker for Ink4a-Arf status and a therapeutic target for high-grade gliomas. 53 62
19805356 2009
2
[Temozolomide: Temodal]. 53 62
18347414 2008
3
Serum GFAP is a diagnostic marker for glioblastoma multiforme. 53 62
17998256 2007
4
The 1p-encoded protein stathmin and resistance of malignant gliomas to nitrosoureas. 53 62
17440165 2007
5
Chromosome 1p and 19q status and p53 and p16 expression patterns as prognostic indicators of oligodendroglial tumors: a clinicopathological study using fluorescence in situ hybridization. 53 62
17319279 2007
6
[Expression of epidermal growth factor receptor and PTEN in malignancy brain tumors]. 53 62
17236582 2006
7
Malignant glioma: neuropathology and neurobiology. 53 62
16944363 2006
8
Frequent promoter hypermethylation and low expression of the MGMT gene in oligodendroglial tumors. 53 62
15455350 2005
9
PTEN is a target of chromosome 10q loss in anaplastic oligodendrogliomas and PTEN alterations are associated with poor prognosis. 53 62
11438483 2001
10
Promoter hypermethylation and homozygous deletion of the p14ARF and p16INK4a genes in oligodendrogliomas. 53 62
11307615 2001
11
Identification of two distinct deleted regions on the short arm of chromosome 1 and rare mutation of the CDKN2C gene from 1p32 in oligodendroglial tumors. 53 62
10515227 1999
12
Reactivation of insulin-like growth factor binding protein 2 expression in glioblastoma multiforme: a revelation by parallel gene expression profiling. 53 62
10485462 1999
13
Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. 53 62
9776413 1998
14
Epidermal growth factor receptor expression in oligodendroglial tumors. 53 62
8686753 1996
15
Lectins: reliable differentiation markers in human oligodendrogliomas. 53 62
8220777 1993
16
Anaplastic oligodendroglioma presenting with apoplectic intratumoral hemorrhage. 62
36439914 2023
17
Relationship between RANO-PRO Working Group standardised priority constructs and disease progression among malignant glioma patients: A retrospective cohort study. 62
36386035 2023
18
Acid and Alkaline Phosphatases Specific activities and Expression as Biomarkers in Brain Tumor Grading and Correlation of Anaplastic Oligodendroglioma G-III to Meningiomas G-I among Brain Tumors and their primary culture. 62
35914649 2022
19
The Multiple Rib Osteomyocutaneous Split Latissimus Dorsi Flap for Calvarial Reconstruction: Indication, Operative Technique, and Review of Literature. 62
35905389 2022
20
Radiosurgery and Stereotactic Brain Radiotherapy with Systemic Therapy in Recurrent High-Grade Gliomas: Is It Feasible? Therapeutic Strategies in Recurrent High-Grade Gliomas. 62
36013284 2022
21
The Mean ApoC1 Serum Level in Postoperative Samples from Neurosurgical Patients Is Lower than in Preoperative Samples and during Chemotherapy. 62
36101402 2022
22
True anaplastic oligoastrocytoma with dual genotype: illustrative case. 62
36046704 2022
23
The correlation analysis of TERT promoter mutations with IDH1/2 mutations and 1p/19q detected in human gliomas. 62
35866817 2022
24
Correction to: [89Zr]Zr‑huJ591 immuno‑PET targeting PSMA in IDH mutant anaplastic oligodendroglioma. 62
35266033 2022
25
The oligodendroglial histological features are not independently predictive of patient prognosis in lower-grade gliomas. 62
35292862 2022
26
A patient with two gliomas with independent oligodendroglioma and glioblastoma biology proved by DNA-methylation profiling: a case report and review of the literature. 62
35018523 2022
27
5-Aminolevulinic acid-enhanced fluorescence-guided treatment of high-grade glioma using angled endoscopic blue light visualization: technical case series with preliminary follow-up. 62
35303704 2022
28
Diagnostic test accuracy and cost-effectiveness of tests for codeletion of chromosomal arms 1p and 19q in people with glioma. 62
35233774 2022
29
Cranial sonolucent prosthesis: a window of opportunity for neuro-oncology (and neuro-surgery). 62
35079911 2022
30
Prognostic value of O6-methylguanine-DNA methyltransferase methylation in isocitrate dehydrogenase mutant gliomas. 62
35386566 2022
31
[89Zr]Zr-huJ591 immuno-PET targeting PSMA in IDH mutant anaplastic oligodendroglioma. 62
34498111 2022
32
Alterations in white matter fiber density associated with structural MRI and metabolic PET lesions following multimodal therapy in glioma patients. 62
36452509 2022
33
Large tumour volume reduction of IDH-mutated anaplastic glioma involving the insular region following radiotherapy. 62
35027006 2022
34
Malignant glioma subset from actuate 1801: Phase I/II study of 9-ING-41, GSK-3β inhibitor, monotherapy or combined with chemotherapy for refractory malignancies. 62
35402914 2022
35
Analysis of the Prognosis of High-Grade gliomas in the View of New Immunohistochemistry Markers and 2016 WHO Classification. 62
35615769 2022
36
Differential expression of stem cell markers in proliferating cells in glioma. 62
34170383 2021
37
Infrequent RAS mutation is not associated with specific histological phenotype in gliomas. 62
34525976 2021
38
Molecular biomarkers and integrated pathological diagnosis in the reclassification of gliomas. 62
34141429 2021
39
Radiation Therapy for Grade 3 Gliomas: Correlation of MRI Findings With Prognosis. 62
34513462 2021
40
TEMOBIC: Phase II Trial of Neoadjuvant Chemotherapy for Unresectable Anaplastic Gliomas: An ANOCEF Study. 62
33783067 2021
41
A single institution retrospective analysis on survival based on treatment paradigms for patients with anaplastic oligodendroglioma. 62
34125374 2021
42
IDH-mutant gliomas with additional class-defining molecular events. 62
33772213 2021
43
[Clinicopathological and molecular genetic characteristics of adult IDH wild-type diffuse gliomas]. 62
34405606 2021
44
Distinct TERT promoter C228T and C250T mutations in a patient with an oligodendroglioma: A case report. 62
33899270 2021
45
Patient-specific virtual reality technology for complex neurosurgical cases: illustrative cases. 62
36046517 2021
46
Gliomas - An experience based on molecular markers. 62
34041176 2021
47
Prolonged benefit to pembrolizumab in anaplastic oligodendroglioma patient with mismatch repair deficiency: a case report. 62
33395066 2021
48
Anaplastic Oligodendroglioma - Is Adjuvant Radiotherapy Mandatory following Maximal Surgical Resection?: Grade 3 Oligo Radiotherapy. 62
33109468 2021
49
Case Report: Detection of Symptomatic Treatment-Related Changes in a Patient With Anaplastic Oligodendroglioma Using FET PET. 62
34868923 2021
50
Establishment and Validation of the Detection of TERT Promoter Mutations by Human Gliomas U251 Cell Lines. 62
34159191 2021

Variations for Anaplastic Oligodendroglioma

ClinVar genetic disease variations for Anaplastic Oligodendroglioma:

5
# Gene Name Type Significance ClinVarId dbSNP ID Position
1 CIC NM_001386298.1(CIC):c.3370C>T (p.Arg1124Trp) SNV Likely Pathogenic
635170 rs1568504941 GRCh37: 19:42791757-42791757
GRCh38: 19:42287605-42287605

Expression for Anaplastic Oligodendroglioma

Search GEO for disease gene expression data for Anaplastic Oligodendroglioma.

Pathways for Anaplastic Oligodendroglioma

Pathways related to Anaplastic Oligodendroglioma according to GeneCards Suite gene sharing:

(show all 40)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.76 PTEN PDGFRA MDM2 KDR EGFR CDKN2C
2 13.7 CDK4 CDKN2B EGFR GFAP KDR MDM2
3
Show member pathways
13.64 CDK4 CDKN2A CDKN2B CDKN2C EGFR KDR
4
Show member pathways
13.43 POT1 MDM2 IDH1 CDKN2C CDKN2B CDKN2A
5
Show member pathways
13.15 CDK4 CDKN2A CDKN2B CDKN2C EGFR KDR
6
Show member pathways
12.89 PTEN PDGFRA MDM2 KDR EGFR CDK4
7 12.76 STMN1 PDGFRA KDR GFAP EGFR
8
Show member pathways
12.62 POT1 MDM2 CDKN2C CDKN2B CDKN2A CDK4
9
Show member pathways
12.57 PTEN MDM2 KDR EGFR CDKN2A CDK4
10 12.47 PTEN IGFBP2 IDH2 IDH1
11
Show member pathways
12.43 CDKN2C CDKN2B CDKN2A CDK4
12 12.43 MGMT MDM2 CDKN2C CDKN2A CDK4
13
Show member pathways
12.41 CDKN2C CDKN2B CDKN2A CDK4
14
Show member pathways
12.37 CDK4 EGFR MDM2 PDGFRA PTEN
15
Show member pathways
12.36 PDGFRA MDM2 KDR EGFR
16 12.22 PTEN PDGFRA KDR EGFR
17 12.11 PTEN PDGFRA MDM2 KDR EGFR CDKN2A
18 12.08 PTEN MDM2 EGFR CDK4
19
Show member pathways
12.07 MDM2 CDKN2C CDKN2B CDKN2A CDK4
20
Show member pathways
12.04 CDK4 CDKN2A CDKN2B CDKN2C
21 12.02 PTEN PDGFRA KDR EGFR
22
Show member pathways
11.99 STMN1 MDM2 GFAP EGFR
23
Show member pathways
11.98 PTEN PDGFRA MDM2 KDR EGFR CDK4
24 11.91 LGALS3 GFAP EGFR CDK4
25 11.87 PTEN MDM2 CDKN2A
26 11.85 OLIG2 OLIG1 GFAP
27 11.83 PTEN CDKN2B CDK4
28
Show member pathways
11.8 EGFR KDR PDGFRA
29 11.76 STMN1 MDM2 CDK4
30 11.73 PTEN PDGFRA KDR EGFR
31 11.66 GFAP OLIG1 OLIG2 PDGFRA
32 11.6 PTEN EGFR CDKN2A CDK4
33 11.55 MDM2 CDKN2A CDK4
34 11.45 CDKN2C CDKN2B CDKN2A CDK4
35 11.42 EGFR KDR PDGFRA
36 11.34 PTEN MDM2 CDK4
37 11.06 MDM2 EGFR CDKN2A CDK4
38 11.04 PTEN KDR EGFR
39 10.96 STMN1 PDGFRA KDR GFAP EGFR
40 10.54 MDM2 CDKN2C CDKN2B CDKN2A CDK4

GO Terms for Anaplastic Oligodendroglioma

Biological processes related to Anaplastic Oligodendroglioma according to GeneCards Suite gene sharing:

(show all 12)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of cell population proliferation GO:0008284 10.23 PTEN PDGFRA MDM2 KDR EGFR CDK4
2 regulation of G1/S transition of mitotic cell cycle GO:2000045 9.99 CDKN2C CDKN2B CDKN2A
3 regulation of cyclin-dependent protein serine/threonine kinase activity GO:0000079 9.97 CDKN2C CDKN2B CDKN2A
4 positive regulation of fibroblast proliferation GO:0048146 9.95 PDGFRA EGFR CDK4
5 isocitrate metabolic process GO:0006102 9.73 IDH2 IDH1
6 response to organic cyclic compound GO:0014070 9.72 MGMT IGFBP2 IDH1 CDKN2B
7 oligodendrocyte differentiation GO:0048709 9.71 CDKN2C OLIG1 OLIG2
8 positive regulation of phosphorylation GO:0042327 9.67 PDGFRA KDR EGFR
9 negative regulation of phosphorylation GO:0042326 9.63 CDKN2C CDKN2B CDKN2A
10 glyoxylate cycle GO:0006097 9.56 IDH2 IDH1
11 phosphorylation GO:0016310 9.5 PDGFRA KDR EGFR CDKN2C CDKN2B CDKN2A
12 negative regulation of cyclin-dependent protein serine/threonine kinase activity GO:0045736 9.23 PTEN CDKN2C CDKN2B CDKN2A

Molecular functions related to Anaplastic Oligodendroglioma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 transmembrane receptor protein tyrosine kinase activity GO:0004714 9.88 PDGFRA KDR EGFR
2 growth factor binding GO:0019838 9.72 PDGFRA KDR IGFBP2
3 vascular endothelial growth factor receptor activity GO:0005021 9.67 PDGFRA KDR
4 vascular endothelial growth factor binding GO:0038085 9.56 PDGFRA KDR
5 isocitrate dehydrogenase (NADP+) activity GO:0004450 9.46 IDH2 IDH1
6 cyclin-dependent protein serine/threonine kinase inhibitor activity GO:0004861 9.43 CDKN2C CDKN2B CDKN2A
7 kinase activity GO:0016301 9.17 PDGFRA KDR EGFR CDKN2C CDKN2B CDKN2A

Sources for Anaplastic Oligodendroglioma

2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....